← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV27행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
Autologous hematopoietic stem cell infusion (Autologous hematopoietic stem cell infusion)
Institute of Hematology & Blood Di…·Prolonged Cytopenia Following CAR-…
31 trials
Overview
Program
Autologous hematopoietic stem cell infusion
Overview
Company
Institute of Hematology & Blood Diseases Hospital, China
Overview
Modality
CGT
Overview
Target
Prolonged Cytopenia Following CAR-T Ther
Overview
Indication
Prolonged Cytopenia Following CAR-T Therapy
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Technology
Vector
lentiviral vector and used to transduce hematopoietic stem and progenitor cells (HSPCs) fr
MoA
Mechanism
, manufacturing processes and ongoing clinical trials
MoA
Biomarker
biomarker for treatment response and relapse prediction
PK/PD
Species
Mouse, Human
PK/PD
Animal (cat.)
Human, Mouse, In vitro
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Mouse, Human
Toxicology
Animal (cat.)
Human, Mouse, In vitro
Toxicology
Major finding
thrombocytopenia was more common with HD-Ara-C, it was manageable with supportive care
Toxicology
CRS
Reported
Clinical
Safety signal
thrombocytopenia was more common with HD-Ara-C, it was manageable with supportive care
Clinical
Selected reported efficacy
73.33%
Clinical
Result source
ClinicalTrials.gov NCT02722941
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT02722941
Preclinical
Animal (cat.)
Mouse, In vitro